Seidel, Corinna L.
Gerlach, Roman G.
Weider, Matthias
Wölfel, Theresa
Schwarz, Vincent
Ströbel, Armin
Schmetzer, Helga
Bogdan, Christian
Gölz, Lina
Funding for this research was provided by:
University Hospital Prof. Gölz
Universitätsklinikum Erlangen
Article History
Received: 11 February 2022
Accepted: 18 April 2022
First Online: 27 April 2022
Declarations
:
: The study protocol has been approved by the local ethics committee of the Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg (Krankenhausstraße 12, 91054 Erlangen, Vote number: 347_19B) and registered at ClinicalTrials.gov in 2 parts prior to the beginning of the trial: NCT04598633 (adolescents, registration date 10/22/2020,ExternalRef removed) and NCT04606186 (adults, registration date 10/28/2020,ExternalRef removed). Signed informed consent is mandatory prior to the beginning of the study.
: Not applicable.
: The company BioGaia AB provides non-financial support by supply of the <i>Limosilactobacillus reuteri</i> Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) and control lozenges. The design, management, analyses, reporting of the study, interpretation of data and the decision to submit results are entirely independent of the non-financial supporter.